Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.64−0.02 (-3.31%)
Close on Nov 11, 2026Market cap $252.43MP/E 2.9Yield –
Standard BioTools profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Standard BioTools's profit margin for the twelve months ending Jun 30, 2026 was 100.4%. For fiscal 2025 it was -87.8%, against -152.6% the year before. The highest annual figure on record is -23.2% in fiscal 2013.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -87.8% | +64.8 |
| FY2024 | Dec 31, 2024 | -152.6% | −82.4 |
| FY2023 | Dec 31, 2023 | -70.2% | +123.9 |
| FY2022 | Dec 31, 2022 | -194.1% | −148.7 |
| FY2021 | Dec 31, 2021 | -45.4% | −7.0 |
| FY2020 | Dec 31, 2020 | -38.4% | +16.9 |
| FY2019 | Dec 31, 2019 | -55.3% | −3.0 |
| FY2018 | Dec 31, 2018 | -52.2% | +7.1 |
| FY2017 | Dec 31, 2017 | -59.4% | +13.4 |
| FY2016 | Dec 31, 2016 | -72.8% | −26.3 |
| FY2015 | Dec 31, 2015 | -46.5% | −1.1 |
| FY2014 | Dec 31, 2014 | -45.4% | −22.1 |
| FY2013 | Dec 31, 2013 | -23.2% | +13.1 |
| FY2012 | Dec 31, 2012 | -36.4% | +16.1 |
| FY2011 | Dec 31, 2011 | -52.4% | −2.1 |
| FY2010 | Dec 31, 2010 | -50.4% | +24.9 |
| FY2009 | Dec 31, 2009 | -75.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -133.1% | +20.7 |
| Q1 FY2026 | Mar 31, 2026 | 600.9% | +729.6 |
| Q4 FY2025 | Dec 31, 2025 | 81.0% | +218.6 |
| Q3 FY2025 | Sep 30, 2025 | -177.4% | −55.4 |
| Q2 FY2025 | Jun 30, 2025 | -153.7% | +49.5 |
| Q1 FY2025 | Mar 31, 2025 | -128.7% | −58.1 |
| Q4 FY2024 | Dec 31, 2024 | -137.5% | −67.4 |
| Q3 FY2024 | Sep 30, 2024 | -122.0% | −39.2 |
| Q2 FY2024 | Jun 30, 2024 | -203.3% | −141.7 |
| Q1 FY2024 | Mar 31, 2024 | -70.6% | −3.6 |
| Q4 FY2023 | Dec 31, 2023 | -70.2% | +7.0 |
| Q3 FY2023 | Sep 30, 2023 | -82.8% | +32.0 |
| Q2 FY2023 | Jun 30, 2023 | -61.6% | +276.8 |
| Q1 FY2023 | Mar 31, 2023 | -67.1% | +220.8 |
| Q4 FY2022 | Dec 31, 2022 | -77.1% | −52.5 |
| Q3 FY2022 | Sep 30, 2022 | -114.7% | −66.2 |
| Q2 FY2022 | Jun 30, 2022 | -338.4% | −283.1 |
| Q1 FY2022 | Mar 31, 2022 | -287.8% | −230.4 |
| Q4 FY2021 | Dec 31, 2021 | -24.6% | +15.8 |
| Q3 FY2021 | Sep 30, 2021 | -48.6% | −33.5 |
| Q2 FY2021 | Jun 30, 2021 | -55.3% | −5.3 |
| Q1 FY2021 | Mar 31, 2021 | -57.4% | +0.5 |
| Q4 FY2020 | Dec 31, 2020 | -40.4% | −1.3 |
| Q3 FY2020 | Sep 30, 2020 | -15.0% | +33.6 |
| Q2 FY2020 | Jun 30, 2020 | -49.9% | −1.2 |
| Q1 FY2020 | Mar 31, 2020 | -57.9% | +26.7 |
| Q4 FY2019 | Dec 31, 2019 | -39.1% | +6.6 |
| Q3 FY2019 | Sep 30, 2019 | -48.6% | +2.3 |
| Q2 FY2019 | Jun 30, 2019 | -48.8% | +12.7 |
| Q1 FY2019 | Mar 31, 2019 | -84.6% | −32.1 |
| Q4 FY2018 | Dec 31, 2018 | -45.7% | −8.0 |
| Q3 FY2018 | Sep 30, 2018 | -50.9% | +13.5 |
| Q2 FY2018 | Jun 30, 2018 | -61.5% | +9.4 |
| Q1 FY2018 | Mar 31, 2018 | -52.5% | +14.9 |
| Q4 FY2017 | Dec 31, 2017 | -37.7% | +32.9 |
| Q3 FY2017 | Sep 30, 2017 | -64.4% | +24.7 |
| Q2 FY2017 | Jun 30, 2017 | -70.8% | – |
| Q1 FY2017 | Mar 31, 2017 | -67.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -70.5% | – |
| Q3 FY2016 | Sep 30, 2016 | -89.2% | – |
See a number that looks wrong?